Acrivon Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
/ 
Frequently asked questions
To buy Acrivon Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Acrivon Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Acrivon Therapeutics Inc. is ACRV:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Acrivon Therapeutics Inc. has its primary listing on NASDAQ. You can trade Acrivon Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Acrivon Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Acrivon Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Acrivon Therapeutics Inc..